Poster Session 3-6 PNH/Hemolytic anemia

[PS3-6-2] Interim analysis of post marketing surveillance on PNH: long-term intervention with eculizumab

Hideyoshi Noji^1,11,12, Yasutaka Ueda^2,12, Naoshi Obara^3,12, Yoshinobu Kanda^4,12, Shinichiro Okamoto^5,12, Kensuke Usuki^6,12, Takahisa Matsuda⁷, Hirozumi Akiyama⁷, Masanori Takahashi⁷, Yuji Yonemura^8,12, Tatsuya Kawaguchi^9,12, Jun-Ichi Nishimura^2,12, Takayuki Ikezoe^1,12, Shigeru Chiba^3,12, Yuzuru Kanakura^2,12, Haruhiko Ninomiya^10,12 (1.Department of Hematology, Fukushima Medical University, Fukushima, Japan., 2.Department of Hematology and Oncology, Osaka University, Suita, Japan., 3.Department of Hematology, Faculty_of_Medicine, University of Tsukuba, Tsukuba, Japan., 4.Division of Hematology, Jichi Medical University, Shimotsuke, Japan., 5.Division of Hematology, Department of Internal_Medicine, Keio University, Tokyo, Japan., 6.Department of Hematology, NTT Medical Center Tokyo, Tokyo Japan., 7.Alexion Pharma G.K., Tokyo, Japan, 8.Department of Transfusion_Medicine and Cell_Therapy, Blood_Transfusion_Service, Kumamoto University, Kumamoto, Japan., 9.Kumamoto Health Science University, Kumamoto, Japan., 10.Department of Medical_Sciences, Faculty_of_Medicine, University of Tsukuba, Tsukuba, Japan., 11.Department of Medical_Oncology, Fukushima Medical University, Fukushima, Japan., 12.Japan PNH Study Group, Tokyo, Japan)